Blog

FSD Pharma Inc. announces $55 million dollar indoor cannabis grow partnership expansion at its Cobourg facility

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJuly 3, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to provide an update on the progress of the joint venture between its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma) and Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”). Continue Reading

FSD Pharma Breaks All-Time Weekly Stock Volume Trading Record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 25, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the last 5 consecutive days of trading, the company traded exactly 269,961,050 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading

FSD Pharma Inc. Announces Appointment of Chief Commercial Officer

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 21, 2018 /CNW/ – Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to announce the appointment of Mr. Michael Ash as the Chief Commercial Officer of FV Pharma Inc. (“FV Pharma”), a wholly-owned subsidiary of the Company. Continue Reading

FSD Pharma Inc. Announces a Partnership Agreement with Cannara Biotech Inc. to Allow for Indoor Grow Space to Increase to a Combined 1,245,000 Square Feet

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

TORONTOJune 19, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “The Company”) (CSE:HUGE), announced the signing of a partnership agreement between FV Pharma Inc. (“FV Pharma”), a wholly-owned subsidiary of the Company, and Cannara Biotech Inc. (“Cannara”) effective May 31, 2018. Continue Reading

FSD Pharma Inc. Added to the CSE 25 Composite Index

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 18, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) has been added to the CSE 25 Composite Index, effective after the close on Friday, June 15, 2018. Continue Reading

FSD Pharma Inc. Announces Appointment of New Director

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company“) (CSE: HUGE), is pleased to announce the appointment of Mr. Anthony Durkacz to its Board of Directors, effective immediately. Continue Reading

FSD Pharma breaks all-time weekly volume trading record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 7, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the first 5 consecutive days of trading, the company traded exactly 259,230,820 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading

FSD Pharma secures exclusive rights in Canada for line of proprietary products and premium access to cannabinoid science research platform in Israel


TORONTOJune 6, 2018 /CNW/ – FSD Pharma Inc. (the “Company”) (CSE: HUGE), is pleased to announce that its wholly- owned subsidiary FV Pharma Inc (“FV Pharma”) have entered into a strategic alliance with SciCann Therapeutics Inc. (“SciCann”) by executing a binding Memorandum of Understanding  (the “MOU“) dated May 28, 2018, Continue Reading